Caregivers we are here to help
Learn effective ways to manage life and loved ones affected by Alzheimers
Join us to help provide support and trusted experience after a diagnosis of Alzheimer's or Dementia for a friend or family member.
Join or start an African American Support Group in your area today.
What is Alzheimer's ?
Alzheimer's is a a degenerative brain disease of unknown cause that causes problems with memory, thinking and behavior. Symptoms usually develop slowly and get worse over time, becoming severe enough to interfere with daily tasks .
read moreWhat do I do now?
How can I help my loved ones impacted by this disease? Touched by Angels Companion and Personal Care Service Aging in place should be a top priority for those we love and those we serve. At Touched by Angels Compassion and Personal Care Service, our goal is to help older adults live their lives how they prefer, and, more often than not, that’s in the homes and communities they love, not an institution. Call for your no obligation consultation: 980-785-4749 or 980-785-4679, you'll be glad you did!
read more
Current Alzheimer’s information
- Differential default mode network trajectories in asymptomatic individuals at risk for Alzheimer's disease May 18, 2019The longitudinal trajectories of functional brain dynamics and the impact of genetic risk factors in individuals at risk for Alzheimer's disease are poorly understood.
- Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease May 18, 2019Blood-based biomarkers of pathophysiological brain amyloid β (Aβ) accumulation, particularly for preclinical target and large-scale interventions, are warranted to effectively enrich Alzheimer's disease clinical trials and management.
- Comparison of 18F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL® approaches: Validation against histopathology May 14, 201918F-florbetaben is currently approved for the visual rule out of β-amyloid (Aβ) pathology. It is also used for recruitment and as an outcome measure in therapeutic trials, requiring accurate and reproducible quantification of Aβ burden in the brain.
- Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint May 11, 2019Identifying clinical measures that track disease in the earliest stages of frontotemporal lobar degeneration (FTLD) is important for clinical trials. Familial FTLD provides a unique paradigm to study early FTLD. Executive dysfunction is a clinically relevant hallmark of FTLD and may be a marker of disease progression.